top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma approvals, new data, M&A activity, and more - April 12th 2024

Immunotherapy company acquired for >$4B & 10 more updates...👇

Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence

🎯 → Approvals

🔬 → New data

🤝 → M&A activity


🎯 FASENRA (benralizumab) received FDA approval for the treatment of children aged 6 to 11 with severe asthma.

VIIV healthcare

🎯 FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older. 

Inozyme Pharma 

🔬 Topline data reported from Ph1/2 trials of INZ-701 in adults with ABCC6 deficiency (PXE) and ENPP1 deficiency showing sustained levels of plasma pyrophosphate (PPi) levels comparable to those observed in Inozyme’s study of healthy subjects. 


🔬 Ph1b topline results reported from ALKS 2680 study showing improved wakefulness in patients w/ narcolepsy type 2 and idiopathic hypersomnia.

Palatin Technologies

🔬 Reported Ph3 PL9643 MELODY-1 Dry Eye Disease (DED) data at ASCRS 2024 showing multiple co-primary and multiple symptom endpoints met suggesting good safety and tolerability profile from the drug.   

RAPT Therapeutics 

🔬 Ph2 trial results indicate Tivumecirnon plus anti-PD-1 immunotherapy has an acceptable safety profile in CPI-experienced head and neck cancer patients. No increase in immune-related toxicity was observed compared to pembrolizumab monotherapy.


🤝 Vertex entered into agreement to acquire Alpine Immune Sciences for $4.9B cash. 

Century Therapeutics

🤝 To acquire Clade Therapeutics for $35M. 


🤝 SciSparc to acquire AutoMax 

Nuvation Bio

🤝 Nuvation Bio completes acquisition of AnHeart Therapeutics.


Interested in these updates? Get the full update each week → 


April 8-12, 2024

Article History:

RF, DV (04/12/24)


bottom of page